Cargando…

Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy

Oncolytic reovirus preferentially targets and kills cancer cells via the process of oncolysis, and additionally drives clinically favorable antitumor T cell responses that form protective immunological memory against cancer relapse. This two-prong attack by reovirus on cancers constitutes the founda...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Vishnupriyan, Giacomantonio, Michael A., Gujar, Shashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070345/ https://www.ncbi.nlm.nih.gov/pubmed/33920168 http://dx.doi.org/10.3390/v13040654

Ejemplares similares

Reovirus in cancer therapy: an evidence-based review
por: Clements, Derek, et al.
Publicado: (2014)

Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
por: Kim, Youra, et al.
Publicado: (2015)

Past, Present and Future of Oncolytic Reovirus
por: Müller, Louise, et al.
Publicado: (2020)

Oncolytic Reovirus in Canine Mast Cell Tumor
por: Hwang, Chung Chew, et al.
Publicado: (2013)

The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006)

Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus
por: Kemp, Vera, et al.
Publicado: (2015)

Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery
por: Kemp, Vera, et al.
Publicado: (2017)

NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma
por: Kennedy, Barry E., et al.
Publicado: (2022)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

The oncolytic effects of reovirus in canine solid tumor cell lines
por: IGASE, Masaya, et al.
Publicado: (2015)

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
por: Kelly, Kevin R., et al.
Publicado: (2017)

IL-6 and IL-10 as predictors of disease severity in COVID-19 patients: results from meta-analysis and regression
por: Dhar, Sujan K., et al.
Publicado: (2021)

Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation
por: Gujar, Shashi A., et al.
Publicado: (2014)

Activation of p53 by Chemotherapeutic Agents Enhances Reovirus Oncolysis
por: Pan, Da, et al.
Publicado: (2013)

Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
por: Cruickshank, Brianne, et al.
Publicado: (2018)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines
por: Holay, Namit, et al.
Publicado: (2017)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus
por: Zhao, Xing, et al.
Publicado: (2017)

Anti-tumor efficacy of oncolytic reovirus against gastrointestinal stromal tumor cells
por: Inagaki, Yusuke, et al.
Publicado: (2017)

Altered Glycan Expression on Breast Cancer Cells Facilitates Infection by T3 Seroptype Oncolytic Reovirus
por: Mohammed, Danahe, et al.
Publicado: (2021)

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
por: Mostafa, Ahmed A., et al.
Publicado: (2018)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

After virus exposure, early bystander naïve CD8 T cell activation relies on NAD(+) salvage metabolism
por: Holay, Namit, et al.
Publicado: (2023)

Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
por: Gujar, Shashi, et al.
Publicado: (2018)

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
por: Sei, Shizuko, et al.
Publicado: (2009)

Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites
por: Jennings, VA, et al.
Publicado: (2014)

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
por: Gujar, Shashi A, et al.
Publicado: (2014)

Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma
por: Cooper, Timothy, et al.
Publicado: (2015)

Correction: Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus
por: Zhao, Xing, et al.
Publicado: (2018)

Kinetics of Oncolytic Reovirus T3D Replication and Growth Pattern in Mesenchymal Stem Cells
por: Banijamali, Razieh Sadat, et al.
Publicado: (2020)

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway
por: Twigger, Katie, et al.
Publicado: (2012)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)

In Vitro Anti-cancer Activity of Adipose-Derived Mesenchymal Stem Cells Increased after Infection with Oncolytic Reovirus
por: Babaei, Abouzar, et al.
Publicado: (2021)

Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus
por: Harryvan, Tom J., et al.
Publicado: (2022)

Naturally occurring reoviruses for human cancer therapy
por: Kim, Manbok
Publicado: (2015)

Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms
por: Gujar, S A, et al.
Publicado: (2014)

Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy
por: Groeneveldt, Christianne, et al.
Publicado: (2022)

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
por: Kelly, Kevin R., et al.
Publicado: (2015)

Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma
por: Islam, Shariful, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bmi104sr81o308n1guhp0oed6j